ResMed Inc. (RMD) has a MoatMap StockRank of 74/100 based on Quality (82/100), Value (43/100), and Momentum (33/100) factor scores. The current signal is BUY. ResMed is a high-quality global leader in sleep apnea devices with high ROIC and strong pricing power. While it is a fantastic business recovering well from competitor recalls, it lacks direct alignment with our 18-month macro themes, making it a lower priority for our highly concentrated book.
ResMed Inc. is a global leader in medical devices and cloud-based software solutions for treating and managing sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Its competitive moat is its innovative product portfolio, extensive patent protection, global distribution network, and leadership in connected health solutions that enhance patient adherence and outcomes. ResMed is a dominant player in sleep and respiratory care, benefiting from a growing addressable market and strong R&D.
| Price | $186.44 |
| Market Cap | $29.5B |
| P/E (TTM) | 20.04 |
| P/E (Forward) | 17.05 |
| Price/Book | 4.65 |
| Return on Equity | 25.2% |
| Return on Invested Capital | 23.6% |
| Debt/Equity | 12.99 |
| Gross Margin | 62.2% |
| Operating Margin | 35.3% |
| Revenue Growth | 10.8% |
| Dividend Yield | 1.1% |
| Free Cash Flow | $1.4B |
ResMed Inc. operates in the Medical Instruments & Supplies industry, part of the Healthcare sector (United States).